These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 18695901)

  • 1. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
    Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
    Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
    J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
    Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
    BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
    Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
    J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
    Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
    Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
    PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.
    Kim HS; Kim WS; Park SH; Jung CW; Choi HY; Lee HM; Jeon SS; Ha H; Hwang IG; Lee S; Lim HY
    Urol Oncol; 2010; 28(2):157-63. PubMed ID: 18976937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
    Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
    Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
    Ananthanarayanan V; Tretiakova M; Husain AN; Krausz T; Antic T
    Am J Clin Pathol; 2014 Jul; 142(1):82-7. PubMed ID: 24926090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
    Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
    Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
    Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
    Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.